Cabaletta Bio, Inc.
NASDAQ:CABA · NASDAQ Global Select
+$0.04 today
Vol 17.18M · Avg 3.33M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CABA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$175.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.97, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $142.7M +46.8% | $97.2M +75.4% | $55.4M +41.0% | $39.3M +20.9% | $32.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $29.6M +5.8% | $27.9M +45.2% | $19.2M +29.6% | $14.8M +7.4% | $13.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $172.2M +37.6% | $125.1M +67.6% | $74.7M +37.9% | $54.1M +16.9% | $46.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.6M -3.8% | $1.7M +20.0% | $1.4M +21.1% | $1.2M +60.7% | $733.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$164.2M -44.8% | -$113.4M -71.2% | -$66.2M -27.9% | -$51.8M -13.7% | -$45.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$172.2M -37.6% | -$125.1M -67.6% | -$74.7M -37.9% | -$54.1M -16.9% | -$46.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.0M -39.8% | $10.0M +43.5% | $7.0M +500.1% | $1.2M +4750.0% | $24.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.0M +167.9% | $748.0K | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.4M -52.7% | $9.3M +32.8% | $7.0M +500.1% | $1.2M +4750.0% | $24.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$167.9M -44.9% | -$115.9M -71.2% | -$67.7M -27.7% | -$53.0M -14.4% | -$46.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$167.9M -44.9% | -$115.9M -71.2% | -$67.7M -27.7% | -$53.0M -14.4% | -$46.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +29.9% | -$2 -41.8% | -$2 +8.8% | -$2 -0.6% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +29.9% | -$2 -41.8% | -$2 +8.8% | -$2 -0.6% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $102.3M +106.5% | $49.5M +20.9% | $40.9M +39.5% | $29.3M +14.0% | $25.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $102.3M +106.7% | $49.5M +20.8% | $40.9M +39.5% | $29.3M +14.0% | $25.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$484.64M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$389.07M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$349.90M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$345.72M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$297.21M
Editas Medicine, Inc.
NASDAQ:EDIT
$252.09M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$194.64M
Humacyte, Inc.
NASDAQ:HUMA
$154.49M
Immutep Limited
NASDAQ:IMMP
$55.41M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CABA generate?
Cabaletta Bio, Inc. (CABA) reported $0.00 of revenue in fiscal 2025.
Is CABA profitable?
Cabaletta Bio, Inc. (CABA) reported -$167,856,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.